Nothing Special   »   [go: up one dir, main page]

Bingfa et al., 2009 - Google Patents

Anti-hepatitis B virus activity and mechanisms of recombinant human serum albumin-interferon-α-2b fusion protein in vitro and in vivo

Bingfa et al., 2009

Document ID
14036737941030316890
Author
Bingfa X
Qinglin F
Hui H
Canjun W
Wei W
Lihua S
Publication year
Publication venue
Pharmacology

External Links

Snippet

Aims: To evaluate the anti-hepatitis B virus (anti-HBV) effects and mechanisms of recombinant human serum albumin-interferon-α-2b fusion protein (rHSA-IFNα-2b) in vitro and in vivo. Methods: The inhibiting effects on HBV replication were examined in the HepG2 …
Continue reading at karger.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application

Similar Documents

Publication Publication Date Title
Tan et al. When hepatitis B virus meets interferons
Isorce et al. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus
Lau et al. Lamivudine for chronic delta hepatitis
Li et al. Interferon and interferon-stimulated genes in HBV treatment
Zhang et al. Antiviral activity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection
Ocama et al. Hepatitis B virus infection: current status
Foster et al. Are all type I human interferons equivalent?
Wong et al. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B
Dong et al. Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: A study on the anti‐hepatitis B virus mechanism of oxymatrine
Schultz et al. Elimination of duck hepatitis B virus RNA-containing capsids in duck interferon-alpha-treated hepatocytes
DK2694087T3 (en) The treatment of infection with Hepatitis B virus alone or in combination with hepatitis delta virus, and in connection with liver diseases
Su et al. The TLR3/IRF1/Type III IFN axis facilitates antiviral responses against enterovirus infections in the intestine
Bhattacharjee et al. Current therapeutics against HCV
De Clercq Current treatment of hepatitis B virus infections
Inoue et al. Small interfering RNA screening for the small GTPase Rab proteins identifies Rab5B as a major regulator of hepatitis B virus production
Tsuge et al. Development of a novel site-specific pegylated interferon beta for antiviral therapy of chronic hepatitis B virus
DebRoy et al. Hepatitis C virus dynamics and cellular gene expression in uPA‐SCID chimeric mice with humanized livers during intravenous silibinin monotherapy
Yang et al. Role of epigenetic modification in interferon treatment of hepatitis B virus infection
Jakschies et al. Strong transient expression of the type I interferon–induced MxA protein in hepatitis A but not in acute hepatitis B and C
Bingfa et al. Anti-hepatitis B virus activity and mechanisms of recombinant human serum albumin-interferon-α-2b fusion protein in vitro and in vivo
Dai et al. Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model
Li et al. Interferon alpha induces cellular autophagy and modulates hepatitis B virus replication
Xu et al. IFIT3 is increased in serum from patients with chronic hepatitis B virus (HBV) infection and promotes the anti-HBV effect of interferon alpha via JAK-STAT2 in vitro
Malaguarnera et al. Serum β2-microglobulin in chronic hepatitis C
Andreakos et al. Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond